(Q35841594)

10 August 2017

1 reference

title

Paclitaxel for non-small cell lung cancer (English)

1 reference

10 August 2017

1 reference

1 reference

Sakkaraiappan Ramalingam

series ordinal

1

1 reference

10 August 2017

Chandra P Belani

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Expert Opinion on Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

1771-1780

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

The taxoids. Comparative clinical pharmacology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Taxanes for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

The discovery of BMS-275183: an orally efficacious novel taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1771

10.1517/14656566.5.8.1771

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference